This journal article explores why the public and stakeholders should help develop guidelines and policies governing scientific practices for controversial biomedical research issues, such as genetically editing human embryos.
Kirstin R.W. Matthews, Ana S. Iltis, Sarah HooverSeptember 22, 2021
The authors sought to develop and test a tool that accurately predicts the unique financial burden to individual patients undergoing treatment for breast cancer. JCO Clinical Cancer Informatics, an American Society of Clinical Oncology Journal
Anaeze C. Offodile II, Chris Sidey-Gibbons, André Pfob, Malke Assad, Stefanos Boukovalas, Yu-Li Lin, Jesse Creed Selber, Charles ButlerMarch 26, 2021
It now seems technically feasible to culture human embryos beyond the “fourteen‐day limit,” which has the potential to increase scientific understanding of human development and perhaps improve infertility treatments. Robust stakeholder engagement preceded adoption of the fourteen‐day limit and should arguably be part of efforts to reassess it, write the authors.
Kirstin R.W. Matthews, Ana S. Iltis, Daniel S. Wagner, Nuria Gallego Marquez, Jason Scott Robert, Inmaculada de Melo-Martín, Marieke Bigg, Sarah Franklin, Soren Holm, Ingrid Metzler, Matteo A. Molè, Jochen Taupitz, Giuseppe Testa, Jeremy SugarmanFebruary 26, 2021
In this study, the authors found that a parental history of ACEs can weaken protective factors — such as resilience and social connections — that could mitigate the risk of perpetuating the trauma in the next generation. Children and Youth Services Review: http://bit.ly/2UmOH95
Lisa Panisch, Catherine LaBrenz, Jennifer Lawson, Beth Gerlach, Patrick S. Tennant, Swetha Nulu, Monica FaulknerFebruary 3, 2020